Atezolizumab-bevacizumab combo continues to win in advanced HCC
12 May 2021
byElvira Manzano
The combination of the immune checkpoint inhibitor atezolizumab and the angiogenesis inhibitor bevacizumab continues to demonstrate significant clinical benefits vs the oral multikinase inhibitor sorafenib in patients with unresectable hepatocellular carcinoma (HCC), according to updated results from the IMbrave150 trial.
